V
Viridian Therapeutics, Inc. (VRDN)
NCM – Real Time Price. Currency in USD
16.86
-0.34 (-1.98%)
At close: May 12, 2026, 4:00 PM EDT
16.80
-0.06 (-0.36%)
After-hours: May 12, 2026, 7:39 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
16.86
-0.34 (-1.98%)
At close: May 12, 2026, 4:00 PM EDT
16.80
-0.06 (-0.36%)
After-hours: May 12, 2026, 7:39 PM EDT
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves’ disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
| Name | Position |
|---|---|
| Dr. Eric N. Olson Ph.D. | Co-Founder & Chairman of Scientific Advisory Board |
| Dr. Marvin H. Caruthers Ph.D. | Co-Founder & Scientific Advisory Board Member |
| Dr. Michael R. Bristow M.D., Ph.D. | Co-Founder & Member of the Scientific Advisory Board |
| Dr. Radhika Tripuraneni M.D., M.P.H. | Chief Medical Officer |
| Mr. Seth Harmon | Chief Financial Officer |
| Mr. Stephen F. Mahoney J.D., MBA | CEO, President & Director |
| Mr. Thomas W. Beetham J.D., MBA | Chief Operating Officer |
| Mr. Vahe Bedian Ph.D. | Co-Founder & Scientific Advisor |
| Ms. Jennifer Tousignant J.D. | Chief Legal Officer & Corporate Secretary |
| Ms. Melissa Manno | Chief Human Resources Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | 305B2 | d161096d305b2.htm |
| 2026-05-05 | 8-K | d20977d8k.htm |
| 2026-04-17 | DEFA14A | d904274ddefa14a.htm |
| 2026-03-30 | 8-K | d27955d8k.htm |
| 2026-02-26 | S-8 | d62671ds8.htm |
| 2026-02-26 | 10-K | vrdn-20251231.htm |
| 2025-11-05 | 8-K | d33707d8k.htm |
| 2025-11-05 | 10-Q | vrdn-20250930.htm |
| 2025-10-23 | 8-K | d27166d8k.htm |
| 2025-10-21 | 8-K | d12120d8k.htm |